Molecular Templates to Present at Upcoming Investor Conferences
17 mai 2022 16h05 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports First Quarter 2022 Financial Results
12 mai 2022 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates’ Presentations at the American Association of Cancer Research (AACR) Annual Meeting 2022 Highlight Potential of ETB Approach
12 avr. 2022 07h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, April 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM, “Molecular Templates” or “MTEM”) a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates to Host Webinar on a Unique Approach to Immuno-Oncology for Solid Tumors
08 avr. 2022 08h00 HE
|
Molecular Templates, Inc.
Event will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am ET AUSTIN, Texas, April 08, 2022 (GLOBE...
Molecular Templates, Inc. Reports Fourth Quarter 2021 Financial Results
28 mars 2022 16h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Strengthens Board of Directors and Management Team
02 mars 2022 08h00 HE
|
Molecular Templates, Inc.
Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq:...
Molecular Templates to Present at the Upcoming Investor Conferences
01 mars 2022 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, March 01, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
30 nov. 2021 17h30 HE
|
Molecular Templates, Inc.
Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in...
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
18 nov. 2021 08h00 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...
Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
15 nov. 2021 07h30 HE
|
Molecular Templates, Inc.
AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and...